Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious disease. Co. is developing its primary product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Adintrevimab is designed to be a neutralizing antibody for both the prevention and treatment of COVID-19. Co. is also evaluating additional neutralizing antibodies targeting the receptor binding domain, as well as other subdomains within the spike protein for COVID-19. We show 5 historical shares outstanding datapoints in our ADGI shares outstanding history coverage, used to compute ADGI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADGI market cap history over the course of time is important for investors
interested in comparing ADGI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADGI versus a peer is one thing; comparing
ADGI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADGI can fluctuate over the course of history.
With this page we aim to empower investors researching ADGI by allowing them to research the ADGI market cap history. |
Free ADGI Email Alerts:
Video: The Importance of Market Cap
